Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

被引:205
作者
Barter, Philip J. [1 ]
Brandrup-Wognsen, Gunnar [2 ,3 ]
Palmer, Mike K. [4 ]
Nicholls, Stephen J. [5 ,6 ,7 ]
机构
[1] Heart Res Inst, Sydney, NSW, Australia
[2] AstraZeneca, Molndal, Sweden
[3] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[4] Univ Keele, Keele ST5 5BG, Staffs, England
[5] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[6] Cleveland Clin, Dept Cell Biol, Cleveland, OH 44106 USA
[7] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44106 USA
关键词
lipids; predictors of response; atorvastatin; rosuvastatin; simvastatin; DENSITY-LIPOPROTEIN CHOLESTEROL; ESTER TRANSFER PROTEIN; PRIMARY HYPERCHOLESTEROLEMIA; CORONARY ATHEROSCLEROSIS; SWITCHING STATINS; ATORVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIAL; EFFICACY;
D O I
10.1194/jlr.P002816
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.-Barter, P.J., G. Brandrup-Wognsen, M. K. Palmer, and S. J. Nicholls. Effect of statins on HDL: a complex process unrelated to changes in LDL: analysis of the VOYAGER Database. J. Lipid Res. 2010. 51: 1546-1553.
引用
收藏
页码:1546 / 1553
页数:8
相关论文
共 36 条
[1]   Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins [J].
Asztalos, Bela F. ;
Le Maulf, Florence ;
Dallal, Gerald E. ;
Stein, Evan ;
Jones, Peter H. ;
Horvath, Katalin V. ;
McTaggart, Fergus ;
Schaefer, Ernst J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05) :681-685
[2]   Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients [J].
Asztalos, BF ;
Horvath, KV ;
McNamara, JR ;
Roheim, PS ;
Rubinstein, JJ ;
Schaefer, EJ .
JOURNAL OF LIPID RESEARCH, 2002, 43 (10) :1701-1707
[3]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[4]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[5]   A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].
Bays, HE ;
Ose, L ;
Fraser, N ;
Tribble, DL ;
Quinto, K ;
Reyes, R ;
Johnson-Levonas, AO ;
Sapre, A ;
Donahue, SR .
CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773
[6]   Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes -: Effect of sex and the LIPC promoter variant [J].
Berk-Planken, IIL ;
Hoogerbrugge, N ;
Stolk, RP ;
Bootsma, AH ;
Jansen, H .
DIABETES CARE, 2003, 26 (02) :427-432
[7]   Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors [J].
Chapman, M. John ;
Le Goff, Wilfried ;
Guerin, Maryse ;
Kontush, Anatol .
EUROPEAN HEART JOURNAL, 2010, 31 (02) :149-164
[8]   Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL [J].
Cheung, MC ;
Zhao, XQ ;
Chait, A ;
Albers, JJ ;
Brown, BG .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (08) :1320-1326
[9]   Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study [J].
Cheung, RC ;
Morrell, JM ;
Kallend, D ;
Watkins, C ;
Schuster, H .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 100 (02) :309-316
[10]  
Collins R, 2003, LANCET, V361, P2005